Tuesday, February 05 16:52:38
Icon, the Dublin-based global provider of clinical trials services, has begun direct trading of its ordinary shares on the NASDAQ index.
This follows the firm's withdrawal from the Irish Stock Exchange on the 30th January and the termination of the ADR programme in accordance with the resolutions approved by the shareholders at the Extraordinary General Meeting of the Company on 17th December 2012.
The company, which is listed under the ticker ICLR, joined the exchange at a price of $29.27 on February 4th, and fell back by almost 1 per cent in early trading.
Yesterday, the company, which provides clinical trials to the pharmaceutical and medical device industries, revealed that it had acquired a US healthcare company in a deal worth $52 million (E38 million).